{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:47:53Z","timestamp":1792226873122,"version":"4.4.0"},"reference-count":45,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009776","name":"McMaster University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009776","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Understanding the effects of burosumab compared to conventional therapy or no treatment on patient-important outcomes in adults with X-linked hypophosphatemia (XLH) is essential to guide evidence-based treatment recommendations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To examine the highest certainty evidence addressing the management of XLH in adults to inform treatment recommendations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched Embase, MEDLINE, Web of Science, and Cochrane Central up to May 2023. Eligible studies included randomized controlled trials (RCTs) and observational studies of individuals aged 18+ with clinically or genetically confirmed XLH. Manuscripts comparing burosumab to no treatment or conventional therapy (phosphate and active vitamin D) and conventional therapy to no treatment were included. Two reviewers independently determined eligibility, extracted data, and assessed risk of bias (RoB). GRADE methodology was used to assess evidence certainty.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We screened 4114 records, after removing duplicates, and assessed 254 full texts. One RCT and 2 observational studies were eligible. The RCT of burosumab vs no treatment had low RoB. Burosumab probably improves pain from fracture\/pseudofracture healing (moderate certainty) but has little or no impact on direct pain measures (moderate certainty). Burosumab may reduce the need for parathyroidectomy (low certainty) but has little or no impact on fatigue (high certainty), stiffness (moderate certainty), and mobility (low certainty) over 24 weeks. Burosumab may increase dental abscess risk (low certainty). Indirect evidence comparing burosumab to conventional therapy provided low certainty regarding burosumab vs conventional therapy. Two observational studies on conventional therapy vs no treatment had high RoB and very low certainty regarding the impact of conventional therapy on patient-important outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>No formal comparisons between burosumab and conventional therapy in adults exist. Evidence for conventional therapy vs no treatment is very uncertain. Our review highlights the need for more data on the long-term effects of burosumab and conventional therapy on patient-important outcomes in adult patients with XLH.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgae890","type":"journal-article","created":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T20:21:21Z","timestamp":1734898881000},"page":"1767-1780","source":"Crossref","is-referenced-by-count":11,"title":["Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Adult Patients With X-Linked Hypophosphatemia"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5378-5548","authenticated-orcid":false,"given":"Dalal S","family":"Ali","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, McMaster University , Hamilton, ON , L8S 4L8","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0576-4208","authenticated-orcid":false,"given":"Reza D","family":"Mirza","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, ON , L8S 4L8","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9426-9702","authenticated-orcid":false,"given":"Farah","family":"Alsarraf","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, McMaster University , Hamilton, ON , L8S 4L8","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7284-4822","authenticated-orcid":false,"given":"Salma","family":"Hussein","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, McMaster University , Hamilton, ON , L8S 4L8","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7830-3237","authenticated-orcid":false,"given":"Hajar","family":"Abu Alrob","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, ON , L8S 4L8","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-127X","authenticated-orcid":false,"given":"Natasha M","family":"Appelman-Dijkstra","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Center for Bone Quality, Leiden University Medical Center , 2300 ZA Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7561-9217","authenticated-orcid":false,"given":"Signe Sparre","family":"Beck-Nielsen","sequence":"additional","affiliation":[{"name":"Centre for Rare Diseases, Aarhus University Hospital , 8200 Aarhus N ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aarhus University , 8200 Aarhus N ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-3970","authenticated-orcid":false,"given":"Martin","family":"Biosse-Duplan","sequence":"additional","affiliation":[{"name":"Department of Oral Medicine, Faculty of Dentistry, UMR 1333, Inserm and APHP, Universit\u00e9 Paris Cit\u00e9 , 75006 Paris ,","place":["France"]},{"name":"Institut Imagine, INSERM 1163 , 75015 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-0592","authenticated-orcid":false,"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[{"name":"Institute of Endocrine and Metabolic Sciences, Vita-Salute San Raffaele University and IRCCS , 20132 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1328-6768","authenticated-orcid":false,"given":"Thomas O","family":"Carpenter","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics (Endocrinology), and Orthopedics and Rehabilitation, Yale University School of Medicine , New Haven, CT 06520 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3463-3936","authenticated-orcid":false,"given":"Catherine","family":"Chaussain","sequence":"additional","affiliation":[{"name":"Department of Oral Medicine, Faculty of Dentistry, UMR 1333, Inserm and APHP, Universit\u00e9 Paris Cit\u00e9 , 75006 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8582-8258","authenticated-orcid":false,"given":"Martine","family":"Cohen-Solal","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Reference Center for Rare Bone Diseases, hopital Lariboisiere , 75010 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1472-4117","authenticated-orcid":false,"given":"Rachel K","family":"Crowley","sequence":"additional","affiliation":[{"name":"Rare Disease Clinical Trial Network, University College Dublin , Dublin 4, D04 T6F4 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1759-8419","authenticated-orcid":false,"given":"Karel","family":"Dandurand","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Universit\u00e9 de Sherbrooke , Sherbrooke, QC , J1N 3C6","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5936-3146","authenticated-orcid":false,"given":"Pablo","family":"Florenzano","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, School of Medicine Pontificia Universidad Cat\u00f3lica de Chile , 8320165 Santiago, Regi\u00f3n Metropolitana, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3610-3469","authenticated-orcid":false,"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Department of Medicine, Tamaki-Aozora Hospital , 779-3125 Tokushima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9623-962X","authenticated-orcid":false,"given":"Claudia","family":"Gagnon","sequence":"additional","affiliation":[{"name":"CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Centre, Endocrinology and Nephrology Axis , Quebec City, QC , G1V 4G2","place":["Canada"]},{"name":"Department of Medicine, Universit\u00e9 Laval , Quebec City, QC , G1V 0A6","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3442-1407","authenticated-orcid":false,"given":"Paul","family":"Goodyer","sequence":"additional","affiliation":[{"name":"Research Institute of the McGill University Health Centre , Montreal, QC , H3H 2L9","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1793-4603","authenticated-orcid":false,"given":"Corinna","family":"Grasemann","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Rare Diseases, Katholisches Klinikum Bochum and Ruhr-University Bochum , 44791 Bochum ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7284-3467","authenticated-orcid":false,"given":"Erik A","family":"Imel","sequence":"additional","affiliation":[{"name":"Department of Medicine and Pediatrics, Indiana University School of Medicine , Indianapolis, IN 46202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9386-7732","authenticated-orcid":false,"given":"Suzanne M","family":"Jan de Beur","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Virginia School of Medicine , Charlottesville, VA 22903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0636-123X","authenticated-orcid":false,"given":"Anna","family":"Lehman","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, University of British Columbia , Vancouver, BC , V6T 1Z4","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2026-9587","authenticated-orcid":false,"given":"E Michael","family":"Lewiecki","sequence":"additional","affiliation":[{"name":"New Mexico Clinical Research & Osteoporosis Center , Albuquerque, NM 87106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9271-0379","authenticated-orcid":false,"given":"Emmett","family":"Morgante","sequence":"additional","affiliation":[{"name":"Department of Kinesiology, University of Waterloo , Waterloo, ON , N2L 3G1","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-9185","authenticated-orcid":false,"given":"Leanne M","family":"Ward","sequence":"additional","affiliation":[{"name":"Children's Hospital of Eastern Ontario, Department of Pediatrics, University of Ottawa , Ottawa, ON , K1H 8L1","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3733-8956","authenticated-orcid":false,"given":"Aliya A","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, McMaster University , Hamilton, ON , L8S 4L8","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2352-5718","authenticated-orcid":false,"given":"Gordon","family":"Guyatt","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, ON , L8S 4L8","place":["Canada"]},{"name":"Department of Medicine, McMaster University , Hamilton, ON , L8S 4L8","place":["Canada"]},{"name":"MAGIC Evidence Ecosystem Foundation , 0456 Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"issue":"5","key":"2025052712561183400_dgae890-B1","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.2005111185","article-title":"Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D","volume":"17","author":"Liu","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2025052712561183400_dgae890-B2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2025052712561183400_dgae890-B3","first-page":"790","article-title":"Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets","volume":"60","author":"Holm","year":"1997","journal-title":"Am J Hum Genet"},{"issue":"11","key":"2025052712561183400_dgae890-B4","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/jbmr.4130","article-title":"Burden of illness in adults with hypophosphatasia: data from the global hypophosphatasia patient registry","volume":"35","author":"Seefried","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2025052712561183400_dgae890-B5","doi-asserted-by":"crossref","first-page":"e871","DOI":"10.1210\/clinem\/dgz203","article-title":"Prevalence and mortality of individuals with X-linked hypophosphatemia: a United Kingdom real-world data analysis","volume":"105","author":"Hawley","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025052712561183400_dgae890-B6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-08-0818","article-title":"Incidence and prevalence of nutritional and hereditary rickets in Southern Denmark","volume":"160","author":"Beck-Nielsen","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2025052712561183400_dgae890-B7","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","article-title":"Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment","volume":"62","author":"Endo","year":"2015","journal-title":"Endocr J"},{"issue":"2","key":"2025052712561183400_dgae890-B8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/EJE-15-0515","article-title":"Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications","volume":"174","author":"Rafaelsen","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025052712561183400_dgae890-B9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13023-020-01434-4","article-title":"The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study","volume":"15","author":"Padidela","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"2025052712561183400_dgae890-B10","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025052712561183400_dgae890-B11","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr Connect"},{"key":"2025052712561183400_dgae890-B12","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025052712561183400_dgae890-B13","unstructured":"Ali DS, Mirza RD, Alsarraf F, et al \u00a02024. Systematic Review: Search Strategy. ResearchGate. doi:10.13140\/RG.2.2.24562.21446. Date of deposit December 2024."},{"key":"2025052712561183400_dgae890-B14"},{"key":"2025052712561183400_dgae890-B15","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"7650","key":"2025052712561183400_dgae890-B16","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.ad","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2025052712561183400_dgae890-B17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jclinepi.2017.05.005","article-title":"GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence","volume":"87","author":"Guyatt","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"2025052712561183400_dgae890-B18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2015.12.007","article-title":"Improving GRADE evidence tables part 1: a randomized trial shows improved understanding of content in summary of findings tables with a new format","volume":"74","author":"Carrasco-Labra","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2025052712561183400_dgae890-B19","author":"Surrogate Endpoint Resources for Drug and Biologic Development"},{"issue":"3","key":"2025052712561183400_dgae890-B20","doi-asserted-by":"crossref","first-page":"e001714","DOI":"10.1136\/rmdopen-2021-001714","article-title":"Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension","volume":"7","author":"Briot","year":"2021","journal-title":"RMD Open"},{"issue":"2","key":"2025052712561183400_dgae890-B21","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1475-6773.2005.0k375.x","article-title":"Commentary\u2014goodbye M(C)ID! Hello MID, where do you come from?","volume":"40","author":"Sch\u00fcnemann","year":"2005","journal-title":"Health Serv Res"},{"issue":"1","key":"2025052712561183400_dgae890-B22","doi-asserted-by":"crossref","first-page":"A11-2","DOI":"10.7326\/ACPJC-2004-140-1-A11","article-title":"Patients at the center: in our practice, and in our use of language","volume":"140","author":"Guyatt","year":"2004","journal-title":"ACP J Club"},{"key":"2025052712561183400_dgae890-B23","first-page":"S870","article-title":"PRO154 confirmatory psychometric validation of the brief pain inventory (BPI-SF) in adult X-linked hypophosphatemia (XLH)","volume":"22","author":"Skrinar","year":"2019","journal-title":"Value Health"},{"key":"2025052712561183400_dgae890-B24","volume-title":"The Brief Pain Inventory User Guide","author":"Cleeland","year":"2009"},{"issue":"5","key":"2025052712561183400_dgae890-B25","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N","article-title":"The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory","volume":"85","author":"Mendoza","year":"1999","journal-title":"Cancer"},{"key":"2025052712561183400_dgae890-B26","author":"The Cochrane Collaboration","year":"2020"},{"issue":"3","key":"2025052712561183400_dgae890-B27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00223-017-0363-3","article-title":"Impact of conventional medical therapy on bone mineral density and bone turnover in adult patients with X-linked hypophosphatemia: a 6-year prospective cohort study","volume":"102","author":"Shanbhogue","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"2025052712561183400_dgae890-B28","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1210\/jc.2009-1671","article-title":"Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations","volume":"95","author":"Imel","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025052712561183400_dgae890-B29","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence\u2014indirectness","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"2025052712561183400_dgae890-B30","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jclinepi.2021.04.014","article-title":"GRADE guidelines 6. Rating the quality of evidence\u2014imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"2025052712561183400_dgae890-B31","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence\u2014inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2025052712561183400_dgae890-B32","unstructured":"Ali DS, Mirza RD, Alsarraf F, et al \u00a02024. Supplementary Material for Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Adult Patients with X-Linked Hypophosphatemia. ResearchGate. doi:10.13140\/RG.2.2.21384.23049. Date of deposit 4 October 2024."},{"issue":"5","key":"2025052712561183400_dgae890-B33","first-page":"S148","article-title":"The WOMAC knee and hip osteoarthritis indices: development, validation, globalization and influence on the development of the AUSCAN hand OA indices","volume":"23","author":"Bellamy","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"14","key":"2025052712561183400_dgae890-B34","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/heartjnl-2019-315906","article-title":"Percutaneous mitral commissurotomy versus surgical commissurotomy for rheumatic mitral stenosis: a systematic review and meta-analysis of randomised controlled trials","volume":"106","author":"Achintya Dinesh","year":"2020","journal-title":"Heart"},{"issue":"7","key":"2025052712561183400_dgae890-B35","doi-asserted-by":"crossref","first-page":"e2649","DOI":"10.1210\/clinem\/dgaa242","article-title":"Enthesopathy, osteoarthritis, and mobility in X-linked hypophosphatemia","volume":"105","author":"Imel","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025052712561183400_dgae890-B36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"2025052712561183400_dgae890-B37","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician's guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2025052712561183400_dgae890-B38","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bone.2019.06.025","article-title":"Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients","volume":"127","author":"DeLacey","year":"2019","journal-title":"Bone"},{"issue":"1","key":"2025052712561183400_dgae890-B39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1210\/clinem\/dgad440","article-title":"Efficacy and safety of burosumab in X-linked hypophosphataemia: systematic review and meta-analysis","volume":"109","author":"Wang","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"10189","key":"2025052712561183400_dgae890-B40","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"issue":"21","key":"2025052712561183400_dgae890-B41","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"2025052712561183400_dgae890-B42","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025052712561183400_dgae890-B43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2025052712561183400_dgae890-B44","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial","volume":"34","author":"Insogna","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2025052712561183400_dgae890-B45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fped.2020.00048","article-title":"Positive response to one-year treatment with burosumab in pediatric patients with X-linked hypophosphatemia","volume":"8","author":"Mart\u00edn Ramos","year":"2020","journal-title":"Front Pediatr"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae890\/61267450\/dgae890.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/6\/1767\/61267450\/dgae890.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/6\/1767\/61267450\/dgae890.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:56:51Z","timestamp":1748365011000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/6\/1767\/7931641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12,23]]},"published-print":{"date-parts":[[2025,5,19]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae890","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2024,12,23]]}}}